SCHEDULE: Grace Therapeutics Stake Held by AIGH Capital

AIGH Capital Management and affiliated entities report a 4.9% stake in Grace Therapeutics, Inc., primarily through exercisable warrants.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Grace Therapeutics, Inc. common stock.
• The reporting persons, AIGH Capital Management, LLC, AIGH Investment Partners, L.L.C., and Mr. Orin Hirschman, jointly hold 814,000 shares of common stock.
• This holding represents 4.9% of the class of securities.
• The reported shares are primarily issuable upon the exercise of warrants.
• Specifically, 814,000 shares are issuable upon exercise of warrants, while 10,742 shares issuable upon exercise of warrants are excluded due to beneficial ownership limitations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of existing holdings and potential future ownership via warrants, without new strategic or financial performance information.

Positives

• The reporting persons hold a significant stake, approaching the 5% threshold that typically triggers more detailed reporting.
• The majority of the reported shares are held via exercisable warrants, suggesting a potential for increased ownership if exercised.

Negatives

• A portion of warrants (10,742 shares) are not currently exercisable due to beneficial ownership limitations, indicating a constraint on immediate share acquisition.

Risks

• Beneficial ownership limitations on warrants may prevent full exercise and thus limit the reporting persons' ability to increase their stake beyond certain thresholds.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings in publicly traded companies. This filing indicates AIGH Capital Management's substantial interest in Grace Therapeutics, Inc., approaching a level that may warrant further monitoring by other market participants.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant ownership block, which could influence market perception and trading activity.
• Management: The disclosed stake by AIGH Capital Management may signal their ongoing interest and potential influence on corporate strategy.

Next Steps

• The reporting persons may exercise their warrants, subject to beneficial ownership limitations, which could increase their stake in Grace Therapeutics, Inc.

Key Dates

Keywords

Schedule 13G, Grace Therapeutics, AIGH Capital Management, Orin Hirschman, Beneficial Ownership, Warrants, SEC Filing, Investment Holding